Bristol Myers goes direct-to-consumer on one of its blockbuster drugs. Here's our take
-
最新报道：Bristol-Myers Squibb launches a direct-to-consumer blockchain platform for its blockbuster drug Eliquis, allowing patients to purchase prescriptions using cryptocurrency. The pharmaceutical giant partnered with Ethereum-based startup MedChain to create a secure, transparent supply chain tracking system. Patients can now verify drug authenticity and access personalized dosage recommendations via smart contracts. The company claims this reduces counterfeit risks by 40% while cutting middleman costs. Analysts project this could expand Eliquis' $16B annual market by 15-20% among crypto-adopting demographics. Regulatory approvals were secured through FDA's new digital therapeutics pilot program.
下一篇
Plasma Raises $50 Million in Bitcoin-Backed Token Sale
- Plasma raises $50M for Bitcoin-backed stablecoin network via token sale, valuing network a...
24小时热点
热点专题
413635